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LETTERS TO THE EDITOR
The Role of
Postoperative
Radiotherapy After
Resection of Stage
III Thymoma
To the Editor:
We read with interest the article by
Chang et al.1 entitled “Postoperative ra-
diotherapy for completely resected stage II
and III thymoma.” They retrospectively
reviewed their 20-year experience with
surgery for epithelial thymic tumors. Their
study group included 76 patients, 59 with
stage II thymoma, but unfortunately only
11 at stage III. Other 50 patients operated
on at their center were excluded from the
study mainly because data were insuffi-
cient. There were 11 patients with addi-
tional metachronous malignancies. The
median follow-up, notwithstanding the
20-year study period, was only 56 months
(5 years). In patients with stage III tu-
mors, 3 of 11 (27%) had recurrence. The
conclusion of the authors was that postop-
erative radiotherapy alone was sufficient
in patients with completely resected inva-
sive thymoma. Exclusion of a large num-
ber of patients (50 patients) may contrib-
ute to decrease in the accuracy of the
study, as often patients lost to follow-up
are those doing worse. In addition, it is not
clear from the text whether patients with
metachronous cancer received chemother-
apy, as reported by other groups.2
We believe that it is incorrect and
potentially misleading, especially for res-
idents and surgeons who face this problem
less often, to draw these conclusions on
the base of the data reported in this retro-
spective study, in particular concerning
patients with stage III thymoma. There
were only 11 patients at this stage and 3
(27%) had recurrence. This is a very
small group, probably the smallest re-
ported in the recent literature. Stage III
tumors require a multidisciplinary ap-
proach, often including both induction
(never required in this small group of
patients) and postoperative treatment, po-
tentially including chemo- and radiother-
apy. Radiotherapy alone has often been
demonstrated insufficient at stage III,3 and
also at stage II, when histology is B3 or C,
or when the mediastinal fat is extensively
infiltrated, chemotherapy has been advo-
cated by our group,4 greatly contributing
to improve outcome.
We would like to ask the authors
whether patients with metachronous cancer
received chemotherapy and whether there
was any recurrence in this group. We would
also like them to comment on the limitations
of their retrospective study that we previ-
ously remarked.
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In Reply:
We excluded 50 patients from
the study not because of lost follow-
ups (we have investigated the status of all
the included patients) but because of in-
sufficient data in their old records or treat-
ments (e.g., missing operation date, start/
end day of radiation, unclear margin status
of the pathology report, or incomplete ra-
diation). Those can be minor problems,
and the data might have been helpful in
increasing the total number of patients in
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TABLE 1. Detailed Information on Patients with Additional Malignancies
Patient
No. Treatment
Masaoka
Stage
Other Primary
Malignancies
Time Relation
with Thymoma
Time
Intervals Chemotherapy
1a Op alone II Prostate Post 3 yr No
2 Op alone II Non-small cell lung
cancer
Post 1.5 yr No
3 Op alone II Advanced gastric cancer Post 6 yr Yes
4 Op alone III Small cell lung cancer Pre 4 yr Yes
5 Op alone III Non-Hodgkins
lymphoma
Pre 5.5 yr Yes
6 Op  RT II Acute lymphoblastic
leukemia
Post 8 mo Yes
7 Op  RT III Cervix cancer Pre 1.5 yr No
8 Op  RT II Esophageal cancer Post 4 yr Yes
9 Op  RT II Malignant fibrous
histiocytoma
Pre 5 mo No
10 Op  RT II Prostate cancer Post 6 mo No
11 Op  RT II Breast cancer Pre 3 mob Yes
a Patient with recurrent thymoma.
b In patient 11, breast cancer and thymoma can be considered as synchronous cancer.
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